BioStock: Aptahem’s CEO sees continued interest in Apta-1

Aptahem is progressing with its first clinical study with sepsis candidate Apta-1. The company has also ramped up activities to showcase the candidate at domestic and international industry conferences, such as BIO-Europe Spring in Switzerland and TIDES Asia in Japan. BioStock talked to CEO Mikael Lindstam to learn more.

Read the full interview with Mikael Lindstam at biostock.se:

https://www.biostock.se/en/2023/03/aptahems-ceo-sees-continued-interest-in-apta-1/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/